266 related articles for article (PubMed ID: 20196149)
1. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
[TBL] [Abstract][Full Text] [Related]
2. Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy.
Li Z; Vermeire S; Bullens D; Ferrante M; Van Steen K; Noman M; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2015 Oct; 21(10):2418-28. PubMed ID: 26308438
[TBL] [Abstract][Full Text] [Related]
3. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
4. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease.
Wang Y; Liu XP; Zhao ZB; Chen JH; Yu CG
J Dig Dis; 2011 Aug; 12(4):286-94. PubMed ID: 21791023
[TBL] [Abstract][Full Text] [Related]
6. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
7. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
[TBL] [Abstract][Full Text] [Related]
8. Crossover Subsets of CD4
Li J; Ueno A; Iacucci M; Fort Gasia M; Jijon HB; Panaccione R; Kaplan GG; Beck PL; Luider J; Barkema HW; Qian J; Gui X; Ghosh S
Dig Dis Sci; 2017 Sep; 62(9):2357-2368. PubMed ID: 28573508
[TBL] [Abstract][Full Text] [Related]
9. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
[TBL] [Abstract][Full Text] [Related]
10. Human Blood and Mucosal Regulatory T Cells Express Activation Markers and Inhibitory Receptors in Inflammatory Bowel Disease.
Lord JD; Shows DM; Chen J; Thirlby RC
PLoS One; 2015; 10(8):e0136485. PubMed ID: 26305224
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis.
Yu QT; Saruta M; Avanesyan A; Fleshner PR; Banham AH; Papadakis KA
Inflamm Bowel Dis; 2007 Feb; 13(2):191-9. PubMed ID: 17206665
[TBL] [Abstract][Full Text] [Related]
12. Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.
Kim MJ; Lee WY; Choe YH
Gut Liver; 2015 May; 9(3):370-80. PubMed ID: 25071071
[TBL] [Abstract][Full Text] [Related]
13. Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells.
Cook L; Stahl M; Han X; Nazli A; MacDonald KN; Wong MQ; Tsai K; Dizzell S; Jacobson K; Bressler B; Kaushic C; Vallance BA; Steiner TS; Levings MK
Gastroenterology; 2019 Dec; 157(6):1584-1598. PubMed ID: 31513797
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
16. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.
Eastaff-Leung N; Mabarrack N; Barbour A; Cummins A; Barry S
J Clin Immunol; 2010 Jan; 30(1):80-9. PubMed ID: 19936899
[TBL] [Abstract][Full Text] [Related]
17. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease.
Kelsen J; Agnholt J; Hoffmann HJ; Rømer JL; Hvas CL; Dahlerup JF
Clin Exp Immunol; 2005 Sep; 141(3):549-57. PubMed ID: 16045746
[TBL] [Abstract][Full Text] [Related]
18. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
